Xeris Biopharma Reports Third Quarter 2024 Financial Results
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Business Wire
Achieved record total revenue of $54.3M including record product revenue of $52.9MProduct revenue increased 27% versus prior year and 14% over the prior quarterEnded Q3 with $69.4M in cash, cash equivalents and short-term investmentsRaises full-year guidance of total net revenue to $198M-$202M and tightens year-end cash to $68M-$72MHosting conference call and webcast today at 8:30 a.m. ET CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30, 2024.“We are proud to report our record-breaking quarter with total revenue of our $54 million led by strong demand of Recorlev® and Gvoke®. Our product revenue growth of 27% marks the 12th consecutive quarter of over 20% growth," said John Shannon, CEO of Xeris. "We have made
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before Long [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its price target raised by analysts at HC Wainwright from $6.00 to $6.60. They now have a "buy" rating on the stock.MarketBeat
- Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) was downgraded by analysts at Piper Sandler from an "overweight" rating to a "neutral" rating. They now have a $3.00 price target on the stock.MarketBeat
- Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]Yahoo! Finance
XERS
Earnings
- 11/8/24 - Miss
XERS
Sec Filings
- 11/8/24 - Form 10-Q
- 11/8/24 - Form 8-K
- XERS's page on the SEC website